New Imaging Techniques Uncover How Dual Agonist Drugs Target Brain and Pancreas for Diabetes and Obesity
TL;DR Summary
The article discusses the development of fluorescent probes, daLUXendin544 and daLUXendin660, which specifically target GLP1R and GIPR receptors in the pancreas and brain, enabling detailed visualization of cell targets and receptor nanodomains, and providing insights into the cellular mechanisms of dual agonists like tirzepatide for diabetes and obesity treatment.
- Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain Nature
- Lighting up targets of dual agonist therapies for diabetes and obesity Nature
- Imaging approach illuminates how weight loss drugs target the brain and pancreas Medical Xpress
- Oxford and Berlin scientists reveal how new diabetes and obesity drugs work Radcliffe Department of Medicine
- GIPR signaling opens brain’s gate for GLP-1 weight-loss therapy News-Medical
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
54 min
vs 55 min read
Condensed
100%
10,872 → 49 words
Want the full story? Read the original article
Read on Nature